^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Solid Tumor
    Drug:ABSK071 (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    LB316 / 7 - A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models

    Published date:
    03/15/2023
    Excerpt:
    In mouse syngeneic models harboring KrasG12C mutations, ABSK071 also demonstrated synergy with anti PD-1/L1 antibody or other IO reagents.